M&A Deal Summary

Pharmaron Acquires Absorption Systems

On November 9, 2020, Pharmaron acquired life science company Absorption Systems for 138M USD

Acquisition Highlights
  • This is Pharmaron’s 4th transaction in the Life Science sector.
  • This is Pharmaron’s largest (disclosed) transaction.
  • This is Pharmaron’s 3rd transaction in the United States.
  • This is Pharmaron’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2020-11-09
Target Absorption Systems
Sector Life Science
Buyer(s) Pharmaron
Deal Type Add-on Acquisition
Deal Value 138M USD
Advisor(s) Fairmount Partners (Financial)
Troutman Pepper Hamilton Sanders (Legal)

Target

Absorption Systems

Exton, Pennsylvania, United States
Absorption Systems assists pharmaceutical, biotechnology, and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) barriers in the development of drugs, biologics, and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. Absorption Systems was founded in 1996 and is based in Exton, Pennsylvania.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pharmaron

Beijing, China
Category Company
Founded 2004
Sector Life Science
Employees20,295
Revenue 11.5B CNY (2023)
DESCRIPTION

Pharmaron is a publicly owned, premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, clinical pharmacology, clinical analytical sciences, clinical CRO and SMO, to chemical & pharmaceutical development. With over 10,000 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan, and China. Pharmaron was founded in 2004 and is based in Beijing, China.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 4 of 4
Type (Add-on Acquisition) 3 of 3
State (Pennsylvania) 1 of 1
Country (United States) 3 of 3
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-28 Shin Nippon Biomedical Laboratories Clinical Pharmacology Center

Baltimore, United States

Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc. (SNBL CPC) is a clinical pharmacology facility located in the University of Maryland BioPark in Baltimore, Maryland, USA. The state of the art facility and equipment is bolstered by a vibrant research community. SNBL CPC specializes in complex Phase I-II trials, including TQT/Phase 1 QT de-risking, first-In-human (FIH), Japanese Bridging and Phase II Proof of Concept (POC) studies in therapeutics areas including immunology/infectious disease, neurology, respiratory, dermatology and more.

Buy -
Mergr

Product

Company

Legal